In recent decades, three transmission gases, including nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H~2~S), have been recognized as neurotransmitters or modulators ([@CIT0007]). Among them, H~2~S is a highly poisonous gas with an unpleasant smell. Numerous studies have demonstrated that severe poisoning with H~2~S leads to death, with the active sites of its toxicity primarily the nervous and respiratory systems ([@CIT0008], [@CIT0015]); however, H~2~S can also exert physiological and pathological effects as a signaling molecule ([@CIT0022]). Previous studies have indicated that H~2~S is involved in various biological processes, including oxidative stress, cardiovascular diseases, and inflammatory responses ([@CIT0067]). H~2~S supplementation can activate several anti-oxidative kinases in a mouse model of hyperhomocysteinemia ([@CIT0038]). Further, H~2~S can improve myocardial fibrosis in diabetic rats ([@CIT0032]), hepatotoxicity ([@CIT0029]), and learning and memory of a mouse model for Alzheimer's disease ([@CIT0057]), indicating that H~2~S can mediate protective effects.

Recently, it was reported that H~2~S can significantly affect various physiological and biochemical indicators in model insects. Dietary restriction influences the physiology and lifespan of *Drosophila* by enhancing the transsulfuration pathway, which can produce H~2~S ([@CIT0021]). Further, H~2~S can increase *Drosophila melanogaster* (Diptera: Drosophilidae) survival under arid and food-free conditions ([@CIT0068]), while the lifespan of *Caenorhabditis elegans* (Rhabditida: Rhabditidae) increased after exposure to low concentrations of H~2~S ([@CIT0036]). Moreover, H~2~S increases HIF-1 levels which promotes tolerance of further H~2~S exposure in *C. elegans* ([@CIT0003]), and the *eat-2* mutant, which is a genetic model for lifespan extension, produces H~2~S gas and extends lifespan via calorie restriction ([@CIT0051]). Finally, H~2~S regulates various metabolic processes in *Trypanosoma cruzi* (Kinetoplastida: Trypanosomatidae) ([@CIT0034]).

The silkworm, *Bombyx mori*, is used as a model organism, due to its ideal life cycle, easy cultivation, and economic value ([@CIT0001], [@CIT0055], [@CIT0047]). Feeding silkworms mulberry leaves enriched with vitamins can improve their economic value ([@CIT0023]). Further, mineral supplementation can also positively influence the growth and reproduction of the silkworm ([@CIT0056]) and silkworms fed mulberry leaves soaked in copper exhibited accelerated silk crystallization and intensified the stability and mechanical properties of silkworm protein ([@CIT0006]), while feeding with mulberry leaves containing low concentrations of silver nanoparticles increased the body and cocoon weights of silkworms ([@CIT0035]). Moreover, silkworm larval growth can be promoted by continuous low-dose radiation, whereas it is suppressed by exposure to high doses ([@CIT0037]), and silkworm lifespan is extended by induction with metformin ([@CIT0053]). RNAi-mediated silencing of Yorkie (Yki; a transcriptional co-activator) regulates organ size during animal development and regeneration and causes delayed development and ovary maturation in *B. mori* ([@CIT0060]). Moreover, silkworms injected with titanium dioxide nanoparticles exhibit relatively higher food intake, body weight, and cocoon shell weight, relative to the control group ([@CIT0041]).

Following the establishment of transcriptome and proteomic studies, metabolomics has gradually emerged as promising field for uncovering novel insights into biological processes involving analysis of a comprehensive set of small molecules ([@CIT0054]). Metabolomic profiling studies analyze qualitative and quantitative metabolome differences, to identify potential biomarkers and related metabolic pathways with the aim of unraveling the mechanisms underlying various conditions ([@CIT0039]). Metabolomic profiling of silkworm hemolymph has revealed that phosphorylcholine is the most abundant metabolite in various developmental stages and metabolic pathways, including protein biosynthesis, glycolysis, and the TCA cycle ([@CIT0069]). The peculiar biological function of Filippi's gland in the silk gland of silkworm has also been surveyed through metabolomics, which confirmed that the gland is involved in fatty acid biosynthesis during spinning ([@CIT0058]). The function of glycine in regulating silkworm silk synthesis was confirmed based on gas-chromatography--mass spectrometry metabolomics data ([@CIT0005]). Liquid chromatography--mass spectrometry (LC-MS) is a highly sensitive and specific technique, which can expand metabolite coverage ([@CIT0026], [@CIT0033]); hence, metabolomic profiling using LC-MS is widely applied in metabolomics studies.

To date, H~2~S has been investigated in various model organisms; however, there have been no reports of its effects on silkworm development and it is unclear whether H~2~S can influence silkworm physiological and biochemical processes. In the present study, we used a metabolomics approach to examine the effects of H~2~S on silkworm development and our results reveal the metabolic changes induced in response to H~2~S treatment.

Materials and Methods {#s1}
=====================

Silkworm Strain and Rearing Conditions {#s2}
--------------------------------------

The silkworm strain, *B. mori* P50, was obtained from the Sericulture Research Institute of Chinese Academy of Agricultural Sciences, Zhenjiang, China. Silkworms (strain P50) were reared at 25°C ± 1°C with a photoperiod of 12:12 (L:D) h ([@CIT0010]) and divided into two groups as follows: H~2~S-treated (2.5, 5, 7.5, 10, and 12.5 μM) and controls. Silkworm treatment was initiated on the first day of the fourth-instar stage. There were two modes of H~2~S treatment: in the first, *B. mori* were fed mulberry leaves soaked in H~2~S solution in the desiccator (soaking group; [@CIT0050]), and in the second, *B. mori* were directly fumigated with H~2~S in the desiccator, and then fed with fresh mulberry leaves (fumigating group; [@CIT0067]). H~2~S gas was continuously supplied as NaHS (Shandong West Asia Chemical Company) and monitored using an H~2~S detector in the fumigating group. Silkworms in the control group were fed normal mulberry leaves. Each group was examined in triplicate, with 30 silkworms per replicate. All the silkworms were given abundant mulberry leaves twice per day.

Measurement of Developmental Parameters {#s3}
---------------------------------------

Developmental parameters, including body weight and cocoon production, were investigated in this study, according to the procedures described by [@CIT0019],[@CIT0020]). Cocoon production included cocoon weight, cocoon shell weight, and cocoon shell ratio (%). Total body weight per replicate was recorded each day of the fifth-instar stage. Mortality rate (%) \[(number of dead silkworm/numbers of total silkworm) × 100\] was also measured, as an indicator of optimal H~2~S treatment. Cocoon weight, cocoon shell weight, and cocoon shell ratio (%) \[(cocoon shell weight/cocoon weight) × 100\] were recorded on the fifth day of the pupal stage ([@CIT0050], [@CIT0062]). Mean values of all parameters were used for data analyses.

Metabolite Sample Collection and Pretreatment {#s4}
---------------------------------------------

Silkworm hemolymph was collected from each group on the third day of the fifth-instar stage. All hemolymph specimens were immediately preserved at −80°C for further investigation ([@CIT0061]). Metabolites were extracted from 20-µl aliquots of hemolymph samples using precooled 50% methanol buffer (120 µl), followed by mixing for 1 min, and incubation at 25°C for 10 min. Then, extraction mixtures were stored overnight at −20°C, followed by centrifugation at 4,000 *g* for 20 min and analysis of supernatants by LC-MS. A quality control (QC) group was created using an equal volume of all individual samples to assess the stability of the LC-MS system ([@CIT0031]).

Chromatographic Parameters {#s5}
--------------------------

Samples were initially separated using an ultra-performance liquid chromatography (UPLC) system (SCIEX, United Kingdom). Then, an ACQUITY UPLC T3 column (Waters, United Kingdom) was used for reverse phase separation. According to a previously described method ([@CIT0013]), column temperature was set at 35°C; flow rate was 0.4 ml/min, and injection volume was 4 µl. The mobile phase consisted of mixture A (water and 0.1% formic acid) and mixture B (acetonitrile and 0.1% formic acid). Gradient elution conditions were set as follow: 0--0.5 min, 5% B; 0.5--7 min, 5--100% B; 7--8 min, 100% B; 8--8.1 min, 100--5% B; 8.1--10 min, 5% B.

Mass Spectrometry Conditions {#s6}
----------------------------

A high-resolution tandem mass spectrometer (TripleTOF 5600+; SCIEX) was used to detect eluted metabolites. The Q-TOF was operated under positive and negative ion modes conditions, with ion spray voltage floating set at 5,000 and −4,500 V, respectively. Based on a previous study ([@CIT0004]), curtain gas was set at 30 PSI, ion source gas 1 at 60 PSI, ion source gas 2 at 60 PSI, and an interface heater temperature was maintained at 650°C. Mass spectrometry data were acquired in information-dependent analysis mode. The time-of-flight mass range was from 60 to 1,200 Da, survey scans were obtained at 150 ms per spectrum, and total cycle time was fixed at 0.56 s. Four-time bins were monitored using a 40-GHz multichannel time-to-digital converter detector at a pulser frequency of 11 kHz. Dynamic exclusion was 4 s. To maintain the stability of the system and the reproducibility of sample preparation, QC samples were randomly assessed during the whole acquisition.

Metabolomics Data Processing {#s7}
----------------------------

XCMS and metaX toolbox, implemented using R software, were applied for handling and processing LC-MS raw data files ([@CIT0059]). Acquired MS data were pretreated using XCMS software. Each ion was identified by combining retention time (RT) and *m/z* data and the intensities of each peak recorded. Metabolites were annotated by matching the *m/z* of samples with those from the online KEGG database. An in-house metabolite fragment spectrum library was used to further validate metabolite identities.

Peak intensity data were further preprocessed with metaX using the quality control-robust spline batch correction method ([@CIT0024]). The coefficients of variation (CV) across all QC groups were calculated and metabolite features with CV \>30% removed from the analysis.

Metabolites differentiating between the control and H~2~S-treated groups were identified and analyzed, with the following requirements: VIP scores in PLS-DA (VIP) \> 1, *P* \< 0.05, and fold-change (FC) \> 2 or \< 0.5 ([@CIT0063]). The VIP value was considered as a weighted sum of squares of the PLS weights, reflecting the relative contribution of each *X* variable to the model ([@CIT0027], [@CIT0066] ). Enrichment and pathway analysis were executed using MetaboAnalyst online software (<https://www.metaboanalyst.ca/faces/home.xhtml>). Small metabolites which could not be identified in the KEGG pathway database were classified as unidentified metabolites and excluded from further analyses ([@CIT0028]).

Statistical Analysis {#s8}
--------------------

Data were analyzed by one-way analysis of variance. All data were obtained in triplicate and presented as mean ± SE (*n* = 3). The statistical significance level was set at *P* \< 0.05. For untargeted metabolomics, the Student *t*-test was used to evaluate metabolite differences between the H~2~S-treated and control groups. For multiple tests, *P*-values were calculated using FDR. Supervised PLS-DA was conducted using MetaX to discriminate variables differing among groups.

Results {#s9}
=======

Impact of H~2~S Exposure on Silkworm Development and Cocoon Production {#s10}
----------------------------------------------------------------------

Silkworms were reared in a desiccator under different concentrations of H~2~S (2.5, 5, 7.5, and 12.5 μM) from the fourth- to fifth-instar stages. Body weights of fifth instar larvae were recorded daily. As shown in [Fig. 1](#F1){ref-type="fig"}, on each day of the fifth instar stage, body weights initially rose in response to H~2~S treatment, and then exhibited a declining trend with increasing H~2~S concentration. Weight gain of fifth-instar stage larvae was highest in the group treated with 7.5 μM H~2~S, with mean values of 0.548 ± 0.030 g (*F* = 4.104; df = 5, 11; *P* = 0.024), 0.652 ± 0.045 g (*F* = 3.529; df = 5, 11; *P* = 0.038), 1.020 ± 0.084 g (*F* = 4.913; df = 5, 11; *P* = 0.013), 1.435 ± 0.109 g (*F* = 5.441; df = 5, 11; *P* = 0.009), 1.674 ± 0.113 g (*F* = 5.300; df = 5, 11; *P* = 0.01), and 1.726 ± 0.074 g (*F* = 6.243; df = 5, 11; *P* = 0.005), for initial on day 1--5 weights, respectively (comparisons are relative to untreated controls). Further, cocoon weights of females (*F* = 4.529; df = 5, 10; *P* = 0.02) and males (*F* = 5.077; df = 5, 11; *P* = 0.012) were significantly increased by exposure to 7.5-μM H~2~S treatment compared with the control group ([Fig. 2a](#F2){ref-type="fig"} and [b](#F2){ref-type="fig"}). As shown in [Fig. 2c](#F2){ref-type="fig"} and [d](#F2){ref-type="fig"}, female (*F* = 6.531; df = 5, 10; *P* = 0.006) and male (*F* = 7.994; df = 5, 11; *P* = 0.002) cocoon shell weights were also increased after H~2~S treatment, with a remarkable increase in response to 7.5-μM H~2~S. Likewise, cocoon shell ratio was also increased by 7.5 μM H~2~S (female: *F* = 5.615; df = 5, 10; *P* = 0.010 and male: *F* = 4.548; df = 5, 11; *P* = 0.017; [Fig. 2e](#F2){ref-type="fig"} and [f](#F2){ref-type="fig"}).

![Effects of H~2~S exposure on fifth-instar stage silkworm body weight. Initial body weight (a), and body weight on days one (b), two (c), three (d), four (e), and five (f). Each bar represents the mean and standard error (SE) of three replicates. Different letters above each bar indicate that means differ significantly (*P* ≤ 0.05) from the control.](ieaa008f0001){#F1}

![Effects of H~2~S exposure on silkworm cocoon production. Female (a) and male (b) cocoon weights. Female (c) and male (d) cocoon shell weights. Female (e) and male (f) cocoon shell ratios. Each bar represents the mean and standard error (SE) of three replicates. Different letters above each bar indicate that means differ significantly (*P* ≤ 0.05) from the control.](ieaa008f0002){#F2}

LC-MS Spectrum Analysis and Multivariate Statistics {#s11}
---------------------------------------------------

Total ion chromatography (TIC) data from silkworm hemolymph samples from the H~2~S-treated, control, and QC groups are presented in Supp [Fig. 1 (online only)](#sup1){ref-type="supplementary-material"}. The QC group data indicated metabolite sample quality and showed thorough separation, strong signals, and good reproducibility. Visualization models included unsupervised principal component analysis (PCA) and partial least squares discriminate analysis (PLS-DA). In [Fig. 3](#F3){ref-type="fig"}, the X- and *Y*-axes represent the scores of the first and the second components in the PCA score plot, respectively. The PCA score plot scatter pattern of the control group was wider than that of the H~2~S-treated group, whereas QC group data were gathered in a narrow range, demonstrating that the metabolic model was reliable and that the H~2~S-treated group was well-separated from the control group ([Fig. 3](#F3){ref-type="fig"}). In this study, PLS-DA parameters in the positive and negative modes were *R*^2^*X* = 0.258, *R*^2^*Y* = 0.23, *Q*^2^ = 0.869, and *R*^2^*X* = 0.236, *R*^2^*Y* = 0.153, *Q*^2^ = 0.832, respectively ([Fig. 4](#F4){ref-type="fig"}). These data suggest that the PLS-DA model was stable, effective and well-fitted for prediction. As QC samples were regarded as quality monitors in the metabolic samples; they were not included in further analyses.

![PCA score plots for quality control, control and H~2~S-treated groups. PCA scores indicated separation of metabolites in all groups. (a) PCA in positive mode; (b) PCA in negative mode. ■ Control group; ● H~2~S-treated group; ▲ Quality control group.](ieaa008f0003){#F3}

![PLS-DA analysis of control and H~2~S-treated groups. PLS-DA score plots showing a clear separation of metabolites on exposure to H~2~S. (a) Positive mode (*R*^2^*X* = 0.258, *R*^2^*Y* = 0.23, *Q*^2^ = 0.869); (b) negative mode (*R*^2^*X* = 0.236, *R*^2^*Y* = 0.153, *Q*^2^ = 0.832). ■ Control group; ● H~2~S-treated group.](ieaa008f0004){#F4}

Identification and Metabolic Pathway Analysis of Metabolites Differing Significantly Between the Control and H~2~S-Treated Groups {#s12}
---------------------------------------------------------------------------------------------------------------------------------

Based on VIP, FC, and P-value data, 45 metabolites that differed between the H~2~S-treated and control groups were screened and identified ([Table 1](#T1){ref-type="table"}). To effectively visualize the relative changes on exposure to H~2~S, these 45 significant metabolites were subjected to hierarchical cluster analysis ([Fig. 5](#F5){ref-type="fig"}), which showed that 25 metabolites were increased and 20 decreased in response to H~2~S. Metabolites including thymidine, cytidine, ascorbate, stearidonic acid, (6Z, 9Z, 12Z)-octadecatrienoic acid, icosanoic acid, guanosine 3′-phosphate, and malic acid were significantly increased in the H~2~S-treated group; in contrast, deoxycydine, urate, hexadecanoic acid, biotin, and octadecanoic acid were downregulated. Enrichment analysis using MetPA demonstrated that these metabolites were mainly involved in alpha linolenic acid and linoleic acid, fatty acid, pyrimidine, and purine metabolism ([Fig. 6a](#F6){ref-type="fig"}). The effects of H~2~S on silkworm metabolic pathways were also visualized in the form of a bubble chart ([Fig. 6b](#F6){ref-type="fig"}). Based on *P*-value and pathway impact, the most relevant metabolic pathways were pyrimidine, purine, and fatty acid metabolism, as well as fatty acid elongation in mitochondria, ascorbate and aldarate metabolism, and biotin metabolism.

###### 

Metabolites differing between the H~2~S-treated and control groups

  Metabolite                                                                *m/z*     Retention time (RT)   Log~2~ (FC)   VIP    *P*-value
  ------------------------------------------------------------------------- --------- --------------------- ------------- ------ -----------
  3,4-Dihydroxybenzoate                                                     153.02    0.93                  2.12          2.32   1.20E-02
  3-Dehydroshikimate                                                        171.03    0.90                  3.45          2.98   6.89E-03
  3-Dehydroquinate                                                          189.04    0.91                  3.52          3.40   4.08E-03
  3alpha,7alpha,26-Trihydroxy-5beta-cholestane                              419.35    6.67                  −2.48         3.29   2.60E-02
  Deoxycytidine                                                             226.08    0.94                  −1.34         2.01   2.64E-03
  Thymidine                                                                 241.08    1.60                  1.66          1.87   4.25E-02
  Cytidine                                                                  242.08    0.99                  1.26          1.90   1.79E-02
  Urate                                                                     167.02    1.01                  −1.26         1.56   4.09E-02
  Cortisol                                                                  378.23    3.35                  1.94          1.98   3.40E-02
  Formylisoglutamine                                                        173.06    0.97                  −2.65         2.29   1.18E-02
  Ascorbate                                                                 175.02    1.61                  1.80          2.08   1.37E-02
  5,10-Methylenetetrahydrofolate                                            456.16    2.21                  1.67          2.14   7.12E-03
  [l]{.smallcaps}-Serine-phosphoethanolamine                                227.04    0.98                  −2.29         2.28   1.82E-02
  Stearidonic acid                                                          275.20    3.67                  1.04          1.81   2.61E-03
  5-Dehydro-4-deoxy-[d]{.smallcaps}-glucuronate                             175.02    1.61                  −1.19         1.57   3.86E-02
  gamma-Linolenoyl-CoA                                                      1045.37   2.27                  1.99          2.50   3.40E-04
  (6Z, 9Z, 12Z)-Octadecatrienoic acid                                       279.23    4.73                  1.24          1.92   3.97E-03
  D-Glucuronolactone                                                        194.07    2.34                  −1.27         2.03   9.92E-04
  (9Z, 12Z, 15Z)-Octadecatrienoyl-CoA                                       1045.37   2.27                  2.02          2.58   2.69E-04
  Hexadecanoic acid                                                         279.23    4.73                  −1.04         1.47   1.65E-02
  Icosanoic acid                                                            335.29    6.77                  1.40          1.66   1.80E-02
  [l]{.smallcaps}-Palmitoylcarnitine                                        417.37    6.67                  −1.48         1.56   4.73E-02
  3-Oxooctanoyl-CoA                                                         908.20    2.28                  2.56          2.60   1.26E-03
  Hexadecanal                                                               263.24    3.26                  −1.03         1.46   1.42E-02
  (9Z)-Hexadecenoic acid                                                    255.23    5.58                  −1.02         1.61   2.87E-02
  *N*-Formimino-[l]{.smallcaps}-glutamate                                   175.07    2.21                  −2.73         2.35   1.23E-02
  Ergothioneine                                                             269.06    2.15                  1.75          1.63   4.84E-02
  *N*-Carbamoyl-[l]{.smallcaps}-aspartate                                   177.05    2.50                  −1.47         1.59   3.88E-02
  (S)-Dihydroorotate                                                        181.02    2.68                  1.28          1.55   2.61E-02
  dCTP                                                                      489.98    2.18                  2.37          2.27   1.03E-02
  Allantoate                                                                199.04    1.06                  −1.04         1.63   3.11E-02
  Deoxyadenosine                                                            290.07    2.45                  3.54          2.19   4.72E-02
  5′-Phosphoribosylglycinamide                                              304.09    2.17                  −1.36         1.47   4.03E-02
  GMP                                                                       386.04    2.55                  1.17          1.48   2.78E-02
  UDP-*N*-acetylmuramoyl-[l]{.smallcaps}-alanyl-[d]{.smallcaps}-glutamate   897.22    2.31                  −1.54         1.92   3.93E-02
  Choline phosphate                                                         223.04    0.88                  1.34          1.62   2.57E-02
  [l]{.smallcaps}-Pyrrolysine                                               256.16    2.20                  1.94          2.10   7.46E-03
  6-Hydroxy-3-succinoylpyridine                                             234.02    1.38                  1.38          1.95   1.43E-02
  Biotin                                                                    245.09    2.36                  −1.18         1.60   3.04E-02
  Xylobiose                                                                 281.09    2.55                  2.21          1.98   3.41E-02
  Guanosine 3′-phosphate                                                    386.04    2.55                  1.16          1.57   1.49E-02
  [l]{.smallcaps}-Xylo-hexulonolactone                                      194.07    2.34                  −1.17         1.82   1.36E-02
  Malic acid                                                                133.01    0.99                  3.37          2.94   6.08E-03
  2-(Hydroxymethyl)-3-(acetamidomethylene)succinate                         235.09    2.21                  −2.17         2.16   8.24E-03
  Octadecanoic acid                                                         307.26    6.94                  −2.38         2.47   1.52E-03

![Hierarchical cluster analysis of 45 metabolites differing between the H~2~S-treated and control groups. The color scale indicates the relative metabolite level: red, upregulation; green, downregulation; black, unchanged.](ieaa008f0005){#F5}

![Enrichment and pathway analyses of differential metabolites in silkworm: (a) metabolite enrichment analysis and (b) metabolite pathway analysis. (A) pyrimidine metabolism; (B) purine metabolism; (C) ascorbate and aldarate metabolism; (D) fatty acid metabolism; (E) fatty acid elongation in mitochondria; (F) one carbon by folate; (G) biotin metabolism; (H) methane metabolism.](ieaa008f0006){#F6}

Discussion {#s13}
==========

H~2~S, a novel gaseous signaling molecule, has recently been studied in various model organisms, including mammals ([@CIT0049], [@CIT0057]) and insects ([@CIT0036], [@CIT0051]); however, studies investigating the effects of H~2~S on insects have mainly focused on *Drosophila* and *Caenorhabditis*, and there are no reports on the effects of H~2~S on silkworm to date. This is the first report to investigate the role of H~2~S in silkworm development, by detecting alterations in metabolites in vivo using metabolomics following H~2~S treatment. The two treatment assays (soaking and fumigating) were used after careful review of previous reports ([@CIT0006], [@CIT0067]), and preliminary experiments showed that mortality rates in the soaking group were higher than those in the fumigating group at the same concentration of H~2~S ([Supp Fig. 2 \[online only\])](#sup2){ref-type="supplementary-material"}, possibly due to the relationship between higher humidity and silkworm death ([@CIT0017]); therefore, the fumigating method was adopted for further experiments.

Body weight in the larval stage is a crucial indicator for evaluation of silkworm growth ([@CIT0019]). H~2~S treatment led to higher body weight, relative to the control group, indicating that H~2~S may improve silkworm feeding efficiency ([@CIT0011]). Similarly, a previous study indicated that low concentrations of silver nanoparticles ([@CIT0035]), zinc ([@CIT0002]), and folic acid ([@CIT0046]) could significantly increase silkworm body weight.

Silkworm is one of the most economically important insects with silk the key product accounting for its financial significance ([@CIT0030]). The cocoon shell ratio is a pivotal index that measures energy distribution between silk production and the silkworm. Our results demonstrate that the cocoon shell ratio was increased after H~2~S treatment. Based on these data and previous reports ([@CIT0005], [@CIT0053]), we propose that H~2~S may regulate the relationship between body weight and silk production, promoting silkworm development. Silk production is also increased on treatment with selenium ([@CIT0019]), gold nanoparticles ([@CIT0044]), and a combination of minerals, including N, P, K, and Ca ([@CIT0025]). In this study, the growth parameters of the 7.5-μM H~2~S treatment group of were higher than those of groups treated with other H~2~S concentrations; thus, 7.5 μM can be regarded as the optimal concentration of H~2~S for application in silkworm metabolomic studies. These results indicate that optimal H~2~S supplementation may promote silkworm development in a dose-dependent manner.

Untargeted metabolomic profiling using LC/MS was performed to compare in vivo metabolite changes between H~2~S-treated and control silkworms. The thorough separation, strong signal, and good reproducibility of all metabolites in the two samples indicate that TIC data are good quality ([@CIT0061]). The PCA score plots revealed considerable separation, good reliability, viability, and visualization of data from the H~2~S-treated and control groups ([@CIT0014]). PLS-DA was implemented, based on functions in the partial least squares package, which can evaluate differences among metabolic samples ([@CIT0059], [@CIT0066]). PLS-DA generated numerical and graphical results, which were diagnostic, including *R*^2^ and *Q*^2^. In this study, the metabolites from the two groups were scattered in different sites, indicating that there were significant differences in the metabolites between H~2~S-treated and control group hemolymph.

In total, 45 differential metabolites were identified by metabolomics, primarily, the nucleosides, stearidonic acid, hexadecanoic acid, icosanoic acid, and [l]{.smallcaps}-pyrrolysine; the organic acids, choline phosphate, and guanosine 3'-phosphate; the lipid and lipid-like compounds, deoxyadenosine, (6Z, 9Z, 12Z)-octadecatrienoic acid, dCTP, urate, (9Z)-hexadecenoic acid, and malic acid; the organoheterocyclic compounds, xylobiose, thymidine, and *N*-carbamoyl-[l]{.smallcaps}-aspartate; and ascorbate, which is classified in the phenylpropanoids and polyketides. The metabolite, (6*Z*, 9*Z*, 12*Z*)-octadecatrienoic acid, is an *n*-6 polyunsaturated, essential fatty acid variant of linoleic acid, also referred to as γ- linolenic acid, which decreases pulmonary inflammation by reducing chemotactic factors ([@CIT0012], [@CIT0043]). Levels of (6*Z*, 9*Z*, 12*Z*)-octadecatrienoic acid increased with H~2~S treatment and could potentially decrease inflammation during silkworm development. Levels of malic acid were also increased. Malic acid is an intermediate product of the tricarboxylic acid and glyoxylate cycles ([@CIT0016]). Energy and carbohydrate metabolism were accelerated in silkworm after H~2~S treatment, accompanied by malic acid accumulation, indicating that low concentrations of H~2~S can facilitate silkworm growth. Furthermore, levels of hexadecanoic acid were lower in the H~2~S-treated group than those in the control group. Hexadecanoic acid is a long-chain saturated fatty acid generated by carbohydrates, amino acids, and other fatty acids ([@CIT0009]). An excess of hexadecanoic acid resulted in lipid accumulation-induced lipotoxicity, induction of apoptosis ([@CIT0065]), and release of pro-inflammatory factors ([@CIT0052]). Hexadecanoic acid downregulation after exposure to H~2~S may restrain inflammation in silkworm. Thus, H~2~S may influence silkworm development by regulating fatty acid and energy metabolism.

Enrichment analysis was conducted to directly investigate functionally related metabolites among those identified in our investigation. Nutritional metabolism processes were notably modified in H~2~S-treated silkworms compared with controls ([@CIT0005]); for example, alpha linolenic acid and linoleic acid, as well as fatty acid metabolism. Further, H~2~S also influenced silkworm nucleotide metabolism, including pyrimidine and purine metabolism.

In pathway analysis, larger bubble size indicates greater impact, while deeper orange color represents a lower *P*-value ([@CIT0070]). Endogenous silkworm metabolic processes were regulated by both up and downregulation in response to H~2~S treatment, through modulation of the identified metabolites. Levels of anti-inflammatory metabolites produced by fatty acid metabolism, such as hexadecanoic acid, urate, and octadecanoic acid, were apparently decreased ([Table 1](#T1){ref-type="table"}), signifying that the release of inflammatory factors was hindered by H~2~S ([@CIT0045], [@CIT0064]). A recent study reported the involvement of metabolites related to improved fatty acid metabolism in the silkworm spinning process ([@CIT0058]). Our results show that H~2~S can influence fatty acid metabolism in silkworm, which could potentially impact cocoon production. Further, pyrimidine and purine metabolism are related to nucleotide metabolism, participating in nucleotide anabolism and catabolism ([@CIT0048]). The product of purine metabolism is mainly urate in silkworm, which was reduced in H~2~S-treated silkworms compared with the control group ([Table 1](#T1){ref-type="table"}). Inflammation risk factors are reduced with decreased urate content ([@CIT0040]). In addition, a recent study reports the involvement of pyrimidine metabolism in the silkworm spinning function ([@CIT0058]). Similarly, H~2~S inhibits NF-κB activation in LPS-stimulated macrophages, reducing inflammation ([@CIT0042]). H~2~S can also significantly inhibit TNF-α production, further indicating that it has anti-inflammatory properties ([@CIT0018]). To map the differential metabolites to various pathways, we drew a metabolic network according to KEGG database data ([Fig. 7](#F7){ref-type="fig"}), which primarily comprised pyrimidine, purine, and fatty acid metabolism. Overall, the results of metabolite and pathway analyses demonstrate that H~2~S likely influences silkworm cocoon production and inflammation, providing new perspectives on silkworm developmental responses to H~2~S supplementation.

![Overview of metabolic pathway networks, according to KEGG database data. Red and blue represent high and low levels of metabolites, respectively.](ieaa008f0007){#F7}

To conclude, after continuous treatment with H~2~S led to relative increases in developmental parameters, including body weight, cocoon weight, cocoon shell weight, and cocoon shell ratio, compared with the control group. These developmental parameters were highest following treatment with 7.5-μM H~2~S, relative to other H~2~S concentrations; therefore, 7.5-μM H~2~S can be regarded as the optimal concentration for application in metabolomic studies of silkworm. Untargeted LC-MS-based metabolomic analysis was applied to analyze silkworm hemolymph, enabling improved understanding of changes in metabolites during silkworm development. After exposure to H~2~S, 45 hemolymph metabolites were identified as exhibiting differences in silkworm. Various metabolites responsible for inflammation, including (6Z, 9Z, 12Z)-octadecatrienoic acid and malic acid, were upregulated, while hexadecanoic acid metabolites were downregulated, compared with the control group, resulting in reduced inflammation. Further, metabolites involved in fatty acid, pyrimidine, and purine metabolism, which are closely linked to spinning function and inflammation in silkworm, were altered in response to H~2~S treatment. Hence, developmental parameters and metabolites involved in silkworm spinning function and inflammation were altered in response to H~2~S, by unknown mechanisms, which will be the focus of further study. Together, these results provide novel prospects to help elucidate the role of H~2~S in the physiological and metabolic processes of silkworm.
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